Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Repurposed diabetes drugs boost CAR T therapy effectiveness in bladder cancer

Urothelial carcinoma (UC) is the second most common genitourinary cancer, leading to over 16,000 deaths a year in the United States. Despite recent advances, the 5-year survival rate for metastatic UC remains around five to ten percent. The first FDA-approved

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Urothelial carcinoma (UC) is the second most common genitourinary cancer, leading to over 16,000 deaths a year in the United States. Despite recent advances, the 5-year survival rate for metastatic UC remains around five to ten percent.

The first FDA-approved antibody-drug conjugate therapy for metastatic UC (mUC), enfortumab vedotin (EV) targets NECTIN4, a protein which is expressed on the cell surface of bladder cancer cells, and is now the front-line, standard of care treatment for patients with advanced urothelial carcinoma in the United States. While EV monotherapy leads to at least a 40% response rate in most patients with mUC, in patients whose malignancy is treatment resistant, meaningful improvement in long-term remissions and overall survival are rare.

To improve treatment rates for these patients, UCSF researchers designed a CAR T cell therapy and combined it with an older class of diabetes drugs called thiazolidinediones, to enhance NECTIN4 expression and make tumor cells more susceptible to NECTIN4-CAR T therapy.

Their research appears September 10 in Nature Communications.

We sought to understand how cancer cells regulated expression of NECTIN4, and whether we could leverage that information to enhance NECTIN4 expression and increase the efficacy of the CAR T therapy. We found that a pathway which typically controls fat metabolism called PPAR gamma, facilitates NECTIN4 expression. Interestingly, we repurposed an old class of diabetes drugs – rosiglitazone and pioglitazone – which stimulate PPAR gamma, to enhance NECTIN4 expression." Jonathan Chou, MD, PhD, study senior author, assistant professor in the UCSF Division of Hematology/Oncology

The researchers, led by former UCSF medical student Kevin Chang, MD, had previously found that the expression of NECTIN4 was very heterogeneous. For surface-protein targeting therapies like CAR T cells, the level of the tumor-target dictated how well the therapy worked.

They also tested whether bladder cancer cells that were resistant to one type of NECTIN4-targeted therapy were still sensitive to NECTIN4 CAR T cells. In collaboration with Carissa Chu, MD, assistant professor in the UCSF Department of Urology and colleagues at the Memorial Sloan Kettering Cancer Center, the researchers examined biopsies from patients before starting EV and after progressing on EV, and found that the majority of tumors still retained NECTIN4 expression. By first priming the bladder cancer tumors with rosiglitazone, the researchers were able to increase the efficacy of the NECTIN4 CAR T cells therapy in cell line and animal models.

"By identifying and using a strategy to turn low-expressing tumors into higher-expressing tumors in both EV-naïve and EV-resistant settings, we made the tumor cells more susceptible to NECTIN4-CAR T therapy," said Chou. "These preclinical results lay the groundwork for further CAR T cell development in bladder cancer and urothelial carcinomas and suggest drug combinations that will expand the therapeutic window of NECTIN4-targeting therapies."

Chang, K., et al. (2025). Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer. Nature Communications. doi.org/10.1038/s41467-025-62710-0

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01What are carbs?

Your weight loss plan should keep you healthy and strong as you lose the extra weight. Many plans include a diet low in carbohydrates. Carb cycling is a method of optimizing your carbohydrate intake to meet your needs while dieting, fasting, and working out. When you're carb cycling, you consume carbs to meet your needs on some days and avoid them on other days. The aim of carb cycling is to consume carbohydrates when your body needs them and exclude them at other times. Such strategies in your diet plan can help your weight loss efforts. Carbohydrates, or carbs, are a significant part of the average human diet. Along with proteins and fats, they make up the bulk of your daily meals. Most carbohydrates are broken down by your body into glucose to provide energy for your cells and tissues. Carbohydrates in your diet are of three types — sugars, starches, and fiber. Sugars are simple carbs. Glucose, sugar (sucrose), lactose found in milk, and fructose found in fruits, are naturally occurring sugars. Your body metabolizes these molecules rapidly to yield energy. Starches are complex carbs. They're large molecules that consist of hundreds of molecules of simple sugars joined together. Your body needs to break them down to release energy. Starches are found in bread, potatoes, peas, corn, cereals, and pasta. Fiber is also a complex carbohydrate. Human bodies can't break down these large molecules, so they provide no energy. They're usually excreted as they are in the feces. They add bulk to your meal, so you feel full. Fiber in the diet helps avoid constipation and lowers blood sugar and cholesterol levels. Carbohydrates are an essential part of your diet. A typical diet provides 45% to 65% of its calories from carbohydrates. If you have 2,000 calories a day, you should have about 275 grams of carbohydrates. Always try to choose healthy foods for your carb intake:

Source: www.medicinenet.com ↗
02Your early research focused on predicting molecular properties such as solubility using machine learning. What did that teach you about data-driven property prediction?

Data-driven models, such as Quantitative Structure Activity Relationships (QSAR), are incredibly attractive because they offer rapid methods for predicting molecular properties, including those that are difficult to access through fundamental chemical and physical theory. For new molecules, in related regions of chemical space to the training data, they can often be very accurate. The challenge is that they typically do not generalize across large diverse chemical and biological spaces. Therefore real care is needed when applying them to novel chemistry or biology. Some attempts to build more widely applicable QSAR models have been made in recent years, but most models in use today are still built for specific chemistries and properties owing to the scale and complexity of chemical space. When I started this work, especially for solubility predictions, the datasets were modest by today’s standards, often hundreds to a few thousand molecules. One of the first things that teaches you is to explore the data carefully, assess its quality and quantity, and only then move forward with modeling. The aim is to capture genuine relationships between numerical molecular descriptions and important target endpoints, but those relationships may be only locally generalizable. I also think the phrase “simple descriptors” is interesting. Some are simple, such as atom counts or bond counts, but others rely on detailed parameterization, group contributions, and graph-theoretical techniques. We still see these descriptors used today, sometimes alongside embeddings from graph neural networks or language models. The main lesson for me is that there is no single workflow. Each dataset, model, and end-use case needs careful thought.

Source: www.news-medical.net ↗
03How does vitamin D strengthen the immune system?

More specifically, the study showed that the female patient produced very few cathelicidins, which is a natural toxin found in the immune cells of the lungs needed to fight tuberculosis. In most people infected by tuberculosis, tuberculosis bacteria attack the immune cells of the lungs. The immune cells fight the bacteria by eating them. But the tuberculosis bacterium has developed various evasive mechanisms that reduce the immune cells’ ability to digest and thus to kill the Mtb. “You could say that the tuberculosis bacterium has developed a way to lull the immune cells to sleep. This enables the disease the hide inside the immune cells, making it invisible to other parts of the immune system,” Martin Kongsbak-Wismann explains. This is where vitamin D enters the picture. Because vitamin D is able to counteract the soporific effect of the tuberculosis bacteria by making the immune cells produce more of the cathelicidin toxin. “Cathelicidin is like a microscopic needle that is able to pierce the tuberculosis bacteria. And when it does, it weakens the bacteria’s soporific effect on the immune cells. This restores the immune cells’ ability to kill tuberculosis bacteria,” says Martin Kongsbak-Wismann and adds: “We were amazed by the effect of vitamin D. In immune cells from healthy control subjects, vitamin D improved the cells’ ability to fight Mtb, whereas in the female patient’s immune cells we saw no response to vitamin D. This shows that vitamin D is key to the immune system’s ability to fight Mtb and prevent tuberculosis.” Al-Jaberi, F.A.H., et al. (2022) Reduced vitamin D-induced cathelicidin production and killing of Mycobacterium tuberculosis in macrophages from a patient with a non-functional vitamin D receptor: A case report. Frontiers in Immunology. doi.org/10.3389/fimmu.2022.1038960.

Source: www.news-medical.net ↗
04How long does it take for vitamins to work?

Biologically, vitamins are absorbed within hours and have instant metabolic effects, such as antioxidants that protect cells or compounds that are building blocks for making hormones. But, many factors impact their efficiency and could keep your body from fully absorbing them. Absorption and effects depend on each individual and what combination of vitamins they take. Gender, age, digestive health, medical conditions, and diet all play a role. One helpful practice to detect deficiencies is to look for the symptoms deficiencies create. Then, look for improvement in your symptoms with supplement intake. You are unlikely to see or feel changes if you do not lack nutrients. If you are chronically tired or see signs of unhealthy nails, hair, or skin, supplements may help as these are indicators that you are lacking nutrients in your diet. If you are unsure, your doctor can order tests to check for deficiencies in your blood.

Source: www.medicinenet.com ↗
05Can you please give an overview of BenevolentBio?

What we're trying to do here at Benevolent is develop systems and processes that allow us to tap into the huge amount of public information and some propriety databases that we have paid to access and through that, generate hypotheses which our scientists can then triage. We've got over ten times the amount of information in our database at present (and it’s growing) than we believe that companies such as Watson have. Bringing that and filtering the signals from the ‘noise’ to our experienced drug discovery chemists and biologists, means, firstly, we can reduce the amount of time we take to triage new hypotheses, and secondly, we can develop more predictive chemical tools to allow us to make better molecules and also to reposition existing molecules for new indication.

Source: www.news-medical.net ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →